

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Translated from Hebrew)

	December	
	2020	2019
Assets	NIS in thousands	
CURRENT ASSETS:		
Cash and cash equivalents	25,532	28,392
Receivables:		
Trade receivables	7,862	3,925
Other receivables	9,053	1,934
Current tax assets	-	363
Inventory	19,977	12,195
Biological assets	1,866	1,957
	<u>64,290</u>	<u>48,766</u>
NON-CURRENT ASSETS:		
Property, plant and equipment	11,706	8,699
Operating lease right of use assets	2,021	1,932
Investments in associates	5,461	1,474
Financial assets	9,496	6,257
	<u>28,684</u>	<u>18,362</u>
TOTAL ASSETS	<u>92,974</u>	<u>67,128</u>
Liabilities and equity		
CURRENT LIABILITIES -		
Accounts payable:		
Trade payables	1,045	876
Other payables	3,699	1,492
Deferred and contingent liabilities	4,748	13,533
	<u>9,492</u>	<u>15,901</u>
NON-CURRENT LIABILITIES:		
Deferred tax liability	2,363	2,571
Operating lease liabilities	1,754	1,782
Retirement benefits liabilities, net	115	113
	<u>4,232</u>	<u>4,466</u>
EQUITY:		
Share capital and share premium	62,140	49,430
Other equity reserves	9,053	1,241
Accumulated earnings (loss)	8,057	(3,910)
	<u>79,250</u>	<u>46,761</u>
TOTAL LIABILITIES AND EQUITY	<u>92,974</u>	<u>67,128</u>

Seach*

MEDICAL GROUP

CONSOLIDATED INCOME STATEMENTS

(Translated from Hebrew)

Year ended December 31

	2020	2019	2018
	NIS in thousands		
Revenue from sales	36,802	28,834	18,549
Cost of sales	15,698	14,970	9,369
GROSS PROFIT BEFORE FAIR VALUE ADJUSTMENTS	21,104	13,864	9,180
Unrealized gain on changes in fair value of biological assets	6,695	7,962	7,045
Fair value changes in biological assets sold	(10,857)	(8,082)	(3,622)
GROSS PROFIT AFTER FAIR VALUE ADJUSTMENTS	16,942	13,744	12,603
Research and development expenses	1,925	1,806	456
Sales and marketing expenses	3,003	2,078	1,436
General and administrative expenses	7,570	5,238	1,730
Listing cost of reverse acquisition	-	28,765	-
Loss from disposal and decrease in holding stake in associates	1,552	783	338
Other income	(5,767)	(876)	(410)
OPERATING INCOME (LOSS)	8,659	(24,050)	9,053
Finance expenses	707	468	156
Finance income	5,347	3,531	1,470
Financial income (expenses), net	4,640	3,063	1,314
INCOME (LOSS) BEFORE TAXES	13,299	(20,987)	10,367
Tax expenses	1,332	1,567	2,352
NET INCOME (LOSS)	11,967	(22,554)	8,015
OTHER COMPREHENSIVE INCOME (LOSS)			
Items that will be reclassified into profit or loss -			
Translation differences, net	28	(1)	-
Items that will not be reclassified into profit or loss -			
Profit (loss) from financial assets at fair value, net of tax	565	(1,518)	(11,718)
TOTAL OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX	593	(1,519)	(11,718)
TOTAL COMPREHENSIVE PROFIT (LOSS)	12,560	(24,073)	(3,703)
PROFIT (LOSS) PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY:			
Basic and diluted	0.04	(0.08)	0.03